We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ACTIVISTS: FDA PLEDGE TO CRACK DOWN ON UNAPPROVED DRUGS FALLS SHORT

ACTIVISTS: FDA PLEDGE TO CRACK DOWN ON UNAPPROVED DRUGS FALLS SHORT

June 9, 2006

The FDA's efforts to eliminate unapproved drugs from the market is more show than substance and seems to be part of an agency trend to tread lightly where industry is involved, an activist group says. But a former FDA official disagrees, arguing that the agency's announcement shows a new dedication to ending the practice.

The agency issued its guidance, Marketed Unapproved Drugs -- Compliance Policy Guide, with the intent of putting industry on notice that the FDA is serious about enforcing the regulations against companies that market drugs without getting agency approval. Unapproved drugs are a "significant and serious drug safety issue that must be addressed," Steven Galson, director of the agency's Center for Drug Evaluation and Research, said during a teleconference announcing the guide.

But this announcement is just "a show" that does not represent a real change in agency policy, Peter Lurie, the deputy director of Public Citizen's Health Research Group, told FDAnews. The group has been asking the FDA to change its policies on unapproved drugs since 1996 to no avail, he said.

The guidance only requests that companies voluntarily provide information on these drugs and submit new drug applications; it does not force them to act, Lurie said. The agency is being "naive" in thinking a mostly voluntary approach will be enough, he said. FDA is working under the "hope that a general fear [of possible enforcement] will cause the industry to do something."

But Marc Scheineson, a partner at the Washington, D.C., law firm Alston & Bird and former FDA associate commissioner for legislative affairs, responds that the agency is in fact "throwing down the gauntlet" to industry by finalizing this guidance. When the FDA first introduced the guidance in 2003, it faced tremendous political pressure from lobbyists representing unapproved manufacturers and some in Congress.

These opponents argued that the guidance was unnecessary. Finalizing the guidance and announcing its intent to enforce against some manufacturers is the FDA saying it "won't be intimidated politically," Scheineson added. But he acknowledged that the question remains whether the agency will aggressively enforce this policy. "Will they put their resources where their mouth is?" he asked.

The FDA also does not plan to recall any drugs that were on the shelves before the agency determines that they were being marketed illegally. This decision continues an agency trend of not going far enough to remove drugs from the market, even when there is a risk to public health, Lurie said. For example, the agency recently announced it would not recall supplies of Abbott Laboratories' attention deficit disorder drug Cylert, even though serious injuries have been associated with the drug. (http://www.fdanews.com/did/5_113/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing